Thus, PI3K inhibitors, as well as inhibitors of the PI3K downstream target AKT, significantly reduced TRF1 telomeric foci and lead to increased telomeric DNA damage and fragility, also impairing the growth of lung and GBM cells (Garcia‐Beccaria et al, 2015; Bejarano et al, 2017). The gene discussed is TERF1; the disease is glioblastoma.